Nature Biotechnology, Published online: 16 September 2026; doi:10.1038/s41587-026-03333-8

A breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA is one of a wave of new drugs developed to tackle resistance to estrogen-receptor-targeted therapies.